An observational study in Intracranial Hemorrhage, Ventriculitis and Intracranial Abscess, sponsored by Christopher P Kellner. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by Christopher P Kellner · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Intracranial Hemorrhages with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Intracranial Hemorrhages · United States.
Among the 63 studies in Intracranial Hemorrhages with a site in United States, this one is the 7th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2025, is one of 19 observational ones, reaches primary completion later than 19 of the 20 other live ones, and was the 53rd registered.
211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.
Browse Intracranial Hemorrhages studies →17 of the 63 studies in Intracranial Hemorrhages with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 8 mo–24 mo
Dr. Kerstin de Wit · Sites in United States, Canada
Ages 65+
Ohio State University · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18–80
Basking Biosciences, Inc. · Sites in United States, Australia, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Intracranial Hemorrhages studies recruiting now, 27 (63%) set no upper age limit and 5 (12%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 6 · Phase 4 7
First in 1987; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is close to the median of 250 across 85 observational studies indexed under Intracranial Hemorrhages.
Median enrollment 50 across the 43 interventional studies, 178 across the 19 observational. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 63 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Christopher P Kellner as lead sponsor.
Christopher P Kellner has 1 study filed under Intracranial Hemorrhages — fewer than ten, so there is no comparison to draw.
6 of the studies in Intracranial Hemorrhages with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04229758Phase 3University of Texas at AustinRestarting Anticoagulation After Traumatic Intracranial Hemorrhage | 2026-12 |
| NCT06632587Thomas Jefferson UniversityTiming Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes | 2026-12-01 |
| NCT05361070University of California, San FranciscoNeonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy | 2027-02-28 |
| NCT07738432University of Wisconsin, MadisonNeuro-MoD: Neuroplasticity With Motor Development | 2027-06 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Intracranial Hemorrhages with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.
The IRRAflow system offers automated irrigation, controlled drainage, and ICP monitoring all in one system for the treatment of intracranial hemorrhage - [Intracerebral hemorrhage (ICH), Intraventricular hemorrhage (IVH), Subarachnoid hemorrhage (SAH), Subdural hematoma (SDH)], intracranial abscess, and ventriculitis.
The analysis of the IRRAS catheter will occur prospectively if it is determined the patient meets the enrollment criteria. All patients enrolled in the trial will receive additional supportive and medical treatment by choice of the treating physician and in accordance with standard of care. Such treatment includes but is not limited to neurointensive care, neuromonitoring, and surgical or endovascular occlusion of identified sources of intracranial hemorrhage (e.g. vascular anomalies, aneurysms, etc.).
The patient population for this study will be comprised of up to 250 patients with primary diagnosis of intracranial hemorrhage (SAH, ICH, IVH, SDH), ventriculitis, or intracranial abscess.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients enrolled into the study will undergo treatment with the IRRAflow device
Device: IRRAflow® CNS (Active Fluid Exchange) System
The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
Residual blood volume by post bleed day 5
The residual blood volume at day 5 will be calculated to determine the efficacy of the IRRAflow system compared to other external ventricular drains (EVDs)
Time frame: Post-procedure day 5
Utility weighted modified Rankin Score
Modified Rankin Scale score at 6 months will be collected to determine patient functional outcomes at 6 months. Scores range from 0 to 6, with 0 indicating no disability and 6 indicating death
Time frame: End of study, at 6 months
Rate of blood clearance
Rate of blood clearance will be calculated based on pre- and post-procedure blood volumes
Time frame: Immediately before and after the procedure
Direct hospitalization costs
Direct hospitalization costs will be determined based on the hospital-reported cost of care for the entirety of the patient's hospital stay
Time frame: Discharge, up to 7 days post procedure
NSICU Length of Stay
Hospital quality metrics will include length of neonatal surgery intensive care unit (NSICU) stay in days
Time frame: Discharge, up to 7 days post procedure
Hospital Length of Stay (LOS)
Hospital quality metrics will include length of hospital stay in days
Time frame: Discharge, up to 7 days post procedure
Proportion of participants needing a shunt
Proportion of participants needing a shunt will be calculated to determine how many patients needed a shunt to treat their hydrocephalus
Time frame: Discharge, up to 7 days post procedure
Plan to share: No — Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. The intention will be to publish together between the principal investigator and the sponsor. Following publication, Mount Sinai will archive and store all associated data on its cloud-based system.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2031, 64 months after the start.
Of 44 non-industry observational studies under Intracranial Hemorrhages, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 130. This study's planned 64 months is close to that.
Counting every sponsor, half of 49 studies reached it within 59 months; a quarter within 21 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.